Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.

Furthermore, when we compared FTi sensitivity based on the zygosity of KRAS mutations, there was an overall tendency for higher sensitivity of heterozygous KRAS mutant cell lines, however, differences did not reach statistical significance (Supplementary Fig. 1 ).

also in 111,027 other papers